Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Translational Cancer Research is Scopus-indexed (Q3, CiteScore 2.6), WoS SCIE. Published by AME Publishing Company.
Checked against the index lists dated .
ISSN 2218-676XVerify ISSN ↗2219-6803Verify ISSN ↗
Publisher: AME Publishing Company
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Radiology, Nuclear Medicine and Imaging | 195 / 361 | 46th | Q3 |
| Oncology | 275 / 428 | 35th | Q3 |
| Cancer Research | 184 / 233 | 21st | Q4 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2012–present, best quartile Q3, CiteScore 2.6.
Translational Cancer Research is Q3 in Radiology, Nuclear Medicine and Imaging (rank 195 of 361), Q3 in Oncology (rank 275 of 428) and Q4 in Cancer Research (rank 184 of 233), by CiteScore 2025.
Translational Cancer Research is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 2.6, which places it in quartile Q3 at the 46th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.524, quartile Q2, with an H-index of 47.
Translational Cancer Research is published by AME Publishing Company. Its print ISSN is 2218-676X and its online ISSN is 2219-6803.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Translational Cancer Research has an h-index of 48 and a 2-year mean of 1.42 citations per paper (OpenAlex). Its Scopus CiteScore is 2.6, quartile Q3. On 2-year citations it ranks #166 of 346 Scopus journals in Radiology, Nuclear Medicine and Imaging.
Translational Cancer Research published 662 papers in 2025; its busiest recent year was 2020 with 829. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2026), authors are most often from China (89.4%), United States (5.6%) and United Kingdom (1%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 34 retracted papers are recorded (4.8 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.